Compare WKEY & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKEY | ADAG |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | Switzerland | China |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.3M | 90.5M |
| IPO Year | N/A | 2021 |
| Metric | WKEY | ADAG |
|---|---|---|
| Price | $7.38 | $2.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $10.50 | $8.00 |
| AVG Volume (30 Days) | 178.4K | ★ 211.8K |
| Earning Date | 09-23-2025 | 08-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,994,000.00 | $103,204.00 |
| Revenue This Year | $32.29 | $4,446.34 |
| Revenue Next Year | $89.83 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.50 | $1.30 |
| 52 Week High | $19.80 | $3.16 |
| Indicator | WKEY | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 39.49 | 72.46 |
| Support Level | $7.31 | $1.69 |
| Resistance Level | $8.68 | $2.94 |
| Average True Range (ATR) | 0.68 | 0.37 |
| MACD | -0.13 | 0.11 |
| Stochastic Oscillator | 2.47 | 83.54 |
WISeKey International Holding Ltd is a cybersecurity company focused on delivering integrated security solutions for the Internet of Things and digital identity ecosystems. It integrates secure semiconductors, cybersecurity software, and a globally recognized Root of Trust (RoT) into products and services that protect users, devices, data and transactions in the internet-connected world. It has two business segments. The IoT segment, which is the key revenue driver, generates revenue from the sale of semiconductor's secure chips. The mPKI segment generates revenues from Digital Certificates, It derives maximum revenue from IoT segment.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.